⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MLYS News
Mineralys Therapeutics, Inc. Common Stock
Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
globenewswire.com
MLYS
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
globenewswire.com
MLYS
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)
globenewswire.com
MLYS
Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
globenewswire.com
MLYS
Form 8-K
sec.gov
MLYS
Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing
globenewswire.com
MLYS
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
globenewswire.com
MLYS
Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference
globenewswire.com
MLYS
Form 8-K
sec.gov
MLYS
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
globenewswire.com
MLYS